o2h Ventures has launched Britain’s first S/EIS investment fund backing biotech therapeutic and related AI opportunities. The geographic scope is UK wide including Oxford and London but will target the growing Cambridge biotech cluster.
Large pharmaceutical companies, such as GSK, AstraZeneca and Pfizer have moved from developing innovation in-house to acquiring innovation externally, forcing up prices for the best science and providing earlier exit opportunities.
The team at o2h have access to some of the most exciting ideas through its live grass roots working relationships fostered with entrepreneurs and scientists over 20 years giving it far earlier access than competitors to the most promising companies.
Sunil & Prashant Shah, the fund managers are brothers and have previously founded, grew and sold Oxygen Healthcare to Piramal Enterprise (NSE: PEL) for a significant amount, demonstrating an understanding of the challenges that target investee companies will face along their growth cycle through to exit.
In the last few months, 6 investments have been made from the fund into Oxford Drug Design (Antibiotics), Metrion (Autoimmune Diseases), DeepMatter (AI-Enabled Chemistry), Somaserve (Bionic Nanoparticle), Exonate (Macular Degenerative Disease), Small Pharma (Depression).
Fund’s independent review reports are available on both MJ Hudson Allenbridge and MICAP platforms. The fund was finalist in the EISA impact awards and Sunil Shah who manages the fund was awarded ‘Business Angel of the Year 2019’ by the UKBAA.
To register for the fund and for more information, please click HERE